Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Terran Biosciences novel PCT patent application shows growing interest in psilocin therapies, says GlobalData

Terran Biosciences has recently published a PCT patent application for unnamed orally administered novel psilocin prodrugs. The biotech platform company joins a growing number of companies developing psilocybin-based drugs, including MindMed and Compass Pathways, two leading companies in the psychedelic therapy space. Terran’s patent filing shows that interest in psilocin therapies is growing, says GlobalData, […]
Read more

Significant unmet need remains for disease-modifying therapies in Alzheimer’s market despite two recent approvals, says GlobalData

The current treatments for Alzheimer’s disease (AD) consist mostly of medications that are aimed at treating the symptoms of the disease. A novel disease-modifying therapy (DMT) that can demonstrate significant efficacy in clinical trials could revolutionize the AD market in a way that the anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs) have been unable to do thus […]
Read more

Nubeqa approval to boost Bayer’s presence in prostate cancer market in Japan, says GlobalData

Following the news that Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) and docetaxel has been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) for use in patients with metastatic prostate cancer; James Donagher, Oncology & Hematology Analyst at GlobalData, offers his view: “Due to Japan’s ageing population, […]
Read more

Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India, says GlobalData

The Central Drugs Standard Control Organisation (CDSCO) approval of AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin heralds a new era of treatment for biliary tract cancer (BTC) in India, where chemotherapy has been the only choice for over a decade. With no potential competition in near future, the British-Swedish pharma major certainly has […]
Read more

Diagnosed prevalent cases of obesity and overweight to reach 292 million in 2031 across 7MM, forecasts GlobalData

The diagnosed prevalent cases of obesity and overweight combined in the seven major markets (7MM*) are projected to increase at an annual growth rate (AGR) of 0.54% from 276.9 million in 2021 to nearly 292.0 million in 2031, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Obesity and Obesity: Epidemiology Forecast to […]
Read more

Chinese regulators focus on homegrown COVID-19 therapies to tackle new variants, says GlobalData

The National Medical Products Administration (NMPA) of China has conditionally approved two homegrown oral drugs Simcere Pharmaceutical’s Xiannuoxin and Shanghai Junshi Biosciences‘ Mindevir for the treatment of mild to moderate COVID-19. Drug regulators in China are focusing on approving homegrown antiviral therapies with the ability to tackle new COVID-19 variants, says GlobalData, a leading data […]
Read more

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

Moderna recently confirmed that its Phase I/II study examining candidate mRNA-3927 is progressing. It also shared that data showed a decrease in the number of metabolic decompensation events (MDEs) in trials of mRNA-3927, and regulators seemed to be supportive of MDE as a primary endpoint for the study. Additionally, Moderna stated that all eligible participants […]
Read more

Trodelvy set to become Gilead’s blockbuster with expanded approval, predicts GlobalData

The FDA recently granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting. Trodelvy gained approval by outperforming traditional chemotherapies in this patient group. The drug is expected to become a standard of care […]
Read more

Clinical hold on 4D Molecular’s Fabry program to rise chances for Sangamo to lead FD gene therapy market, says GlobalData

4D Molecular Therapeutics (4DMT), the California-based biotechnology company focused on developing gene therapies for rare and cardiovascular, pulmonary, and ophthalmic diseases, has recently been issued a clinical hold by the FDA for its Fabry Disease (FD) gene therapy program (4D-310).  4DMT and Sangam Therapeutics are the leading developers in the Fabry disease space, and with […]
Read more

Asundexian phase III trial critical for Bayer to become market leader in anticoagulation to prevent stroke in AF patients, says GlobalData

Following the enrollment of the first patient in Bayer’s Phase III OCEANIC-AF clinical trial of asundexian, a potential anticoagulant for stroke prevention in atrial fibrillation (AF) patients; Amy Murray, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “Despite advances in anticoagulation therapy over the last decade, the increased risk and […]
Read more

Potential association between ROBO2 and anthracycline-related cardiomyopathy in childhood cancer survivors holds important implications, says GlobalData

A genome-wide association study (GWAS) published in the Journal of Clinical Oncology has identified a potential association between a genetic variant, ROBO2, and anthracycline-related cardiomyopathy in childhood cancer survivors. The study has important implications as anthracyclines are a widely used chemotherapy drug class to treat various forms of cancer, with 50-60% of children with cancer […]
Read more

Olezarsen Fast Track FDA approval strengthens Ionis Pharmaceuticals outlook in dyslipidemia space, says GlobalData

Ionis Pharmaceuticals has recently received the US FDA Fast Track designation for its investigational therapy, olezarsen, in patients with familial chylomicronemia syndrome (FCS). Olezarsen is also being investigated in a Phase III clinical trial for severe hypertriglyceridemia (sHTG) in the US and several EU countries, including France, Germany, Italy, and the UK. If approved, olezarsen […]
Read more

Approved CD19 CAR-T agents to treat over 13,000 cancer patients annually by 2031, driving sales of Breyanzi and Yescarta, says GlobalData

The number of blood cancer patients receiving CD19-directed chimeric antigen receptor T-cell (CD19 CAR-T) therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. As such, Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to enjoy a lucrative period of high annual sales over […]
Read more
1 … 37 38 39 40 41 … 108